Confo Therapeutics
Francis Santens is a Principal Scientist and Team Lead Molecular Engineering at Confo Therapeutics, bringing extensive experience in protein engineering and cancer therapy. Formerly, at Precirix, Santens was a Senior Scientist focusing on sdAb R&D in cancer therapy. With a background in innovation and postdoctoral research in glycoengineering, Santens has a strong foundation in protein analytics, modulation of immune effector functions, and cell line development. Education includes a Doctor in Sciences in Biochemistry and Biotechnology from Ghent University.
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.